张向荣：1969年6月生，药学博士，硕士研究生导师。2010年3月到2011年8月在美国德州理工大学药学院博士后工作。近年承主持省级科研课题3项,参加国家重大专项1项，国家自然科学基金3项，校级归国启动科研课题1项。参加省级教改课题1项。作为主要完成人获得沈阳市科技进步奖一等奖1项,辽宁省科技进步奖二等奖1项。获得省自然科学学术成果奖励3项，发表学术论文40余篇，SCI收载20余篇。参编教材3部，专著2部,译著1部,申请专利1项。参编译著《药物生物利用度》 化学工业出版社，参编科学出版社《亚健康与保健食品概论》。为英文期刊 Chem Pharm Bull, Journal of Microencapsulation 和Eur J Drug Metab Pharmacokinet 杂志特约审稿者。培养硕士毕业研究生20余名，本科毕业生40余名。

研究方向：根据难溶性药物理化性质和吸收特点设计药物新剂型并进行药物动力学、药效学评价;应用现代分析手段和研究方法，评价和开发药食同源品。

第一作者或通讯作者发表的代表论文

1. Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit(?) L-100 microspheres. Eur J Drug Metab Pharmacokinet. 2016; 41(3):287-93

2. In Vitro Metabolism of 20(R)-25-Methoxyl-Dammarane-3, 12, 20-Triol from Panax notoginseng in Human, Monkey, Dog, Rat, and Mouse Liver Microsomes. PLOS ONE. 2014, 15;9(4):e94962

3. Enhanced bioavailability of orally administered flurbiprofen by combined use of hydroxypropyl-cyclodextrin and poly (alkyl-cyanoacrylate) nanoparticles. Eur J Drug Metab Pharmacokinet. 2014, 39(1):61-67

4. UPLC-MS/MS-ESI assay for simultaneous determination of magnolol and honokiol in rat plasma Application to pharmacokinetic study after administration emulsion .Journal of Ethnopharmacology. 2014, 155(3):1568-1574

5. Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ. Marine Drugs , 2013,92(2):1901-1907

6. Development and evaluation of press-coated salbutamol sulfate tablet for delayed-release dosage forms. Journal of Drug Delivery Science and Technology, 2012, 22 (4): 335-340

7. Simultaneous determination of Five Active Hydrolysis Ingredients from Panax quinquefolium L. by HPLC-ELSD, Biomedical Chromatography, 2011; 25(6):646-651

8. Development and Validation of a HPLC Method for Quantitation of BA-TPQ, a Novel Iminoquinone Anticancer Agent, and an Initial Pharmacokinetic Study in Mice. Biomedical Chromatography 2011; 25(6):628-634

9. Study of pharmacokinetics of 20(S)-25-methoxyl-dammarane-3b, 12b, 20-triol and its active metabolite after oral and intravenous administration in rat, Xenobiotica, 2009.39 (6): 457–464.

10. KCN 1，a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology. PLOS ONE. 2012, 7(9): e44883